Beta-Blockers after Myocardial Infarction with Normal Ejection Fraction
Anna Meta Dyrvig Kristensen(Frederiksberg Hospital), Borja Ibáñez, Morten Wang Fagerland(Oslo University Hospital), Michael Mæng(Aarhus University Hospital), José A. Barrabés(Centro de Investigación Biomédica en Red), Takeshi Kimura(Municipal Hirakata City Hospital), Stuart Pocock(University of London), Roberto Latini(Mario Negri Institute for Pharmacological Research), Kjell Vikenes(Haukeland University Hospital), Sergio Raposeiras‐Roubín(University Hospital Complex Of Vigo), Tomas Jernberg(Karolinska Institutet), Patric Karlström(Ryhov Hospital Jönköping), Robin Hofmann(Stockholm South General Hospital), Xavier Rosselló(University College London), Michael Hecht Olsen, Bertil Lindahl(Uppsala University), Theis Lange(Aalborg University), Jocelyne Benatar(Auckland City Hospital), Valentı́n Fuster(Spanish National Centre for Cardiovascular Research), Troels Yndigegn(Uppsala University Hospital), David Erlinge(Lund University), Neiko Ozasa(Kyoto University Hospital), Massimo Piepoli, Claes Held(Uppsala University), Eva Prescott(Frederiksberg Hospital), John Munkhaugen(University of Oslo), Arnhild Bakken(Oslo University Hospital), Dan Atar(Oslo University Hospital), Therese Lucia Friis Holmager(Frederiksberg Hospital)
Cited by 39
Related Papers
Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
|New England Journal of Medicine|2009|7.1k
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
2016 European Guidelines on cardiovascular disease prevention in clinical practice
|European Heart Journal|2016|6.5k
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
|New England Journal of Medicine|2021|4.6k
Targeted Temperature Management at 33°C versus 36°C after Cardiac Arrest
|New England Journal of Medicine|2013|2.8k